Clary Clish is Director of the Metabolomics Platform at the Broad Institute of MIT and Harvard, where he is also an Institute Scientist. Prior to joining the Broad Institute, Clishheld senior and executive management positions in the biotechnology industry from 2001-2008, including Vice President of Discovery at Gene Logic Inc. and Director of Metabolite Biochemistry at Beyond Genomics Inc. From 1997-2001, Clish was a postdoctoral fellow and instructor in the laboratory of Dr. Charles Serhan at the Center for Experimental Therapeutics and Reperfusion Injury at Brigham & Women’s Hospital. In the Serhan laboratory, his work focused on understanding the roles of lipid mediators in acute inflammation and its resolution, including his discovery and characterization of a new class of anti-inflammatory lipid mediators that have since been named “resolvins.”